Oscotec CEO Yoon Tae-young receives Innovation Award

Yoon Tae-young, CEO of Oscotec, has been awarded the Innovation Award by the Korean Society of Medicinal Chemistry. The award recognizes his contributions to the pharmaceutical industry through creative technological innovation and the development of first-in-class new drugs.

During the upcoming ceremony at the society's second regular academic conference, Yoon is scheduled to deliver a lecture titled ‘From Target to PoC via Medicinal Chemistry’. He will share insights from his 30-year career in both the United States and South Korea, focusing on the importance of verifying mechanistic hypotheses to achieve proof-of-concept in drug development.

Oscotec has recently achieved several significant milestones in global technology transfers. These include the licensing of the hematologic cancer treatment candidate Sevidople닙 to Agios Pharmaceuticals, an exclusive option agreement for the AML treatment candidate Denfivontinib with Yatiri Bio, and the transfer of the Alzheimer’s candidate ADEL-Y01 to Sanofi.